Mimedx (MDXG) Net Income (2011 - 2026)

Mimedx (MDXG) posted Net Income of -$14.8 million for Q2 2026, down 36.65% sequentially from -$10.9 million in Q1 2026.

Mimedx (MDXG) Net Income (2011 - 2026) Analysis & Trends

Mimedx has reported Net Income for 15 years, with the latest figure at -$14.8 million in Q2 2026.

Quarterly Net Income changed N/A year-over-year to -$14.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$25.7 million (down 11943.32% YoY) and the FY2024 annual result came in at $421000.0, up 104.57% from the prior year.
Net Income retreated to -$14.8 million in Q2 2026 per MDXG's latest filing, from -$10.9 million in the prior quarter.
Over five years, Net Income peaked at $9.8 million in Q4 2022 and troughed at -$14.8 million in Q2 2026.
A 4-year average of -$4.2 million and a median of -$3.0 million in 2023 frame the typical range for Net Income.
The widest YoY moves for Net Income: up 4839.7% in 2022, down 510.91% in 2022.
Over 4 years, Net Income stood at $9.8 million in 2022, then tumbled by 77.73% to $2.2 million in 2023, then plunged by 90.09% to $217000.0 in 2024, then sank by 6938.71% to -$14.8 million in 2026.
According to Business Quant data, Net Income over the past three periods registered -$14.8 million, -$10.9 million, and $217000.0 for Q2 2026, Q1 2026, and Q3 2024 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Income (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	1.10 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	1.30 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	482.00 Mn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-644.37 Mn
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	237.01 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	930.12
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	81.49 Mn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	164.49 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-13.27 Mn
10	Mimedx	622.24 Mn	486.40 Mn	44.38 Mn	-14.84 Mn

Download Data